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Antimicrobial susceptibility testing was conducted with
6 different spirochetal strains (4 strains of Leptospira spp.
and 2 strains of Borrelia burgdorferi) against 3 antimicrobial
agents, commonly used in equine and bovine practice. The
ranges of MIC and MBC of amoxicillin against Leptospira
spp. were 0.05-6.25 µg/ml and 6.25-25.0 µg/ml, respectively.
And the ranges of minimal inhibitory concentration
(MIC) and minimal bactericidal concentration (MBC) of
amoxicillin against B. burgdorferi were 0.05-0.39 µg/ml
and 0.20-0.78 µg/ml, respectively. The ranges of MIC and
MBC of enrofloxacin against Leptospira spp. were 0.05-
0.39 µg/ml and 0.05-0.39 µg/ml, respectively. Two strains
of B. burgdorferi were resistant to enrofloxacin at the highest
concentration tested for MBC (≥100 µg/ml). Therefore, the
potential role of tilmicosin in the treatment of leptospirosis
and borreliosis should be further evaluated in animal
models to understand whether the in vivo studies will
confirm  in vitro results. All spirochetal isolates were
inhibited (MIC) and were killed (MBC) by tilmicosin at
concentrations below the limit of testing (≤0.01 µg/ml).
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Introduction
Leptospirosis is a zoonotic infection with a worldwide
distribution that is associated with both endemic disease and
epidemics, with the incidence of disease being highest in
tropical climates [17]. The number of cases of leptospirosis
diagnosed has increased since 1983 in North America [36].
Lyme disease is a multisystemic disorder caused by infection
with  Borrelia burgdorferi and is the most common tick-
associated illness in North America [4,7,8].
Leptospirosis and Lyme disease have some overlapping
geographic distributions and both can produce acute febrile
disease. Although they may be self-limiting diseases in
some cases, they can also have significant morbidity and
mortality if not prevented or treated. The lack of rapid and
accurate diagnostic testing of leptospirosis and Lyme disease
often dictate empirical therapy for acute febrile illness. As
the differential diagnosis of an acute febrile illness in any
particular setting may be extensive, therapeutics that may
cover a broad range of infectious diseases are desirable.
Doxycycline and penicillin are currently the drugs of choice
in the treatment of human leptospirosis, based chiefly on the
fact that they are the only agents that have been studied in
randomized controlled clinical trials [12,21,29]. Previous
studies have shown that the newer cephalosporins and other
β-lactams, as well as fluoroquinolone antibiotics, all have
good in vitro activity against strains of Leptospira [26,34].
Doxycyline and tetracycline have also been used in the
treatment of equine and canine borreliosis [10,35]. 
Although many in vitro and in vivo studies have been
performed to find an optimal treatment for spirochetal
disease, preferred forms of treatment are still not quite clear.
Moreover, the majority of studies concerning in vitro
susceptibility testing of leptospires and borreliae against
antimicrobial agents were conducted with organisms recovered
from human infections. The antimicrobial susceptibility of
leptospires and borreliae isolated from animals is not well
known. In this investigation, in vitro antimicrobial susceptibility
tests were conducted with 6 spirochetal strains (4 leptospires
and 2 borreliae) isolated from animal clinical cases against 3
antimicrobial agents (amoxicillin, tilmicosin, and enrofloxacin),
which are used in the treatment of animal diseases.
Materials and Methods
Bacterial strains
The four strains of Leptospira spp. (L. kirchneri serovar
Grippotyphosa,  L. interogans serovar Pomona, L.
interogans serovar Canicola, and L. interogans serovar
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Icterohaemorrhagiae) were obtained from National Veterinary
Service Laboratory (USA) and two strains of Borrelia
burdgorferi (B. burdgorferei #15770 isolated from a dog and
B. burdgorferi #2769 isolated from a horse in our laboratory)
were used for this study. All leptospiral and borrelial organisms
were not more than 5 passages. Leptospires had been passed
through hamsters three times before used. Leptospires were
maintained in Ellinghausen McCullough Johnson Harris
(EMJH) medium and borreliae were maintained in Barbour-
Stoenner-Kelly (BSK)-II medium, as previously reported
[5,13].
Antimicrobial agents
Stock antimicrobial solutions of 1 mg/ml of amoxicillin
and tilmicosin, and 0.2 mg/ml of enrofloxacin were prepared
with EMJH or BSK-II medium as suggested in National
Committee for Clinical Laboratory Standards (NCCLS)
document M31-A2 or by their manufacturers [25]. Amoxicillin
was purchased from Sigma-Aldrich (USA), enrofloxacin
was obtained from its manufacturer (Bayer, USA) and
tilmicosin obtained from IDEXX Laboratories (Greensboro,
USA). All stock antimicrobial solutions were stored in one-
time-use aliquots at –70°C.
Quality control and internal validity
L. interrogans serovar Icterohaemorrhagiae was evaluated
by
  the broth microdilution and macrodilution methods.
These methods run 5 times over numerous
 days with several
different EMJH medium lots to determine the
 reproducibility
of our methods. Each replicate run used an individually
prepared medium and inoculum suspension. Quality control
and internal validity test for B. burgdorferi was also conducted
with B. burgdorferi #2769 strain and BSK-II medium.
Susceptibility testing for leptospirae
Broth microdilution and macrodilution susceptibility tests
were performed with a previously described technique [24].
Testing of each combination of strain and drug was performed
in parallel runs by each method, microdilution and macrodilution,
to compare the variability of results within and between the
methods. Two parallel runs were performed at different
times
 to determine the reproducibility of results. For each
isolate and substance, independent experiments were performed
on different days, with minimal inhibitory concentrations
(MICs) and minimal bactericidal concentrations (MBCs)
reported as the median of all three experiments.
Susceptibility testing for Borreliae
Broth macrodilution MICs and MBCs were obtained with
a previously described technique [31].
Statistics
To investigate possible differences in the susceptibility
patterns of the spirochetal species tested, the Kruskal-Wallis
test was performed for all MICs and MBCs of the antibiotics
as determined by our experiments with different spirochetal
isolates. The level of significance was p < 0.05.
Results
Quality control
Quality control (internal-validity) assessment of L. interrogans
serovar Icterohaemorrhagiae showed consistent results (data
not shown). MICs determined by microdilution fell within 2
dilutions of each other for all (100%) of 15 triplicate runs.
Fourteen (93.3%) of 15 MICs determined by the macrodilution
technique were within 2 dilutions of each other. A single
outlier for macrodilution was produced by enrofloxacin. In
macrodilution MBCs, all 15 runs (100%) fell within 2
dilutions of each other, although the majority of results for
amoxicillin fell outside the upper limit of the drug concentration
tested. Quality control assessment of B. burgdorferi showed
consistent results (data not shown). MICs and MBCs
determined by macrodilution fell within 2 dilutions of each
other for all (100%) of 15 runs. An assessment of the
reproducibility of our technique with a single serovar over
numerous days with various lots of media appears to have
produced consistent results with the techniques.
MIC and MBC
MICs and MBCs of each antimicrobial agent for the same
isolate spanned a maximum range of +/-1 dilution around
the median except L. interogans serovar Pomona (Table 1).
While the MICs of Leptospira spp. determined by the
Table 1. In vitro susceptibility of 4 strains of Leptospira spp. to 3 antimicrobial agents (µg/ml)
Amoxicillin Tilmicosin Enrofloxacin
MIC Macro
MBC
MIC Macro
MBC
MIC Macro
MBC Micro Macro Micro Macro Micro Macro
L. Canicola 1.56 1.56 12.5 ≤0.01 ≤0.01 ≤0.01 0.10 0.10 0.10
L. Grippotyphosa 3.13 1.56 12.5 ≤0.01 ≤0.01 ≤0.01 0.20 0.10 0.10
L. Icterohemorrhagiae 0.78. 0.78 25.0 ≤0.01 ≤0.01 0.01 0.20 0.10 0.20
L. Pomona 0.78 0.78 6.25 ≤0.01 ≤0.01 ≤0.01 0.20 0.20 0.39
Range 0.05-6.25 0.10-3.13 6.25-25.0 ≤0.01-0.02 ≤0.01 ≤0.01-0.05 0.10-0.39 0.05-0.20 0.05-0.39In vitro antibiotic susceptibility of Leptospira spp. and Borrelia burgdorferi 357
microdilution method tended to be higher than those
obtained by the macrodilution method, the mean MICs of all
three drugs were within one dilution of each other by the
two methods. Tilmicosin was the most potent antimicrobial
against all Leptospira and Borrelia isolates on a microgram-
per-milliliter basis. All spirochetal isolates were inhibited
(MIC) and were killed (MBC) by tilmicosin at below the
limit of testing (0.01 µg/ml). The ranges of MIC and MBC
of amoxicillin against Leptospira spp. were 0.05-6.25 µg/ml
and 6.25-25.0 µg/ml, respectively. And the ranges of MIC
and MBC of amoxicillin against B. burgdorferi were 0.05-
0.39 µg/ml and 0.20-0.78 µg/ml, respectively. The ranges of
MIC and MBC of enrofloxacin against Leptospira spp. were
0.05-0.39 µg/ml and 0.05-0.39 µg/ml, respectively. Two
strains of B. burgdorferi were resistant to enrofloxacin at the
highest concentration tested for MBC (100 µg/ml) (Table 1
and 2).
Statistical analysis
Statistical analysis, including all measured MICs and
MBCs (n = 144), did not show significant differences in the
tested genospecies. The overall reproducibility seen in our
study was excellent, although amoxicillin had greater
variability than other antimicrobial agents tested.
Discussion
A uniform and standardized method to test antimicrobial
susceptibility against pathogenic spirochetes has not been
established. For borreliae and leptospires, the MIC is generally
considered the drug concentration at which no motile
organisms are observed by dark-field microscopy after 48-
72 h of incubation [2,18]. The MBCs for leptospires and
borreliae are determined by the absence of spirochetes in
subcultures on microscopic examination after various
incubation periods [18]. The MBC determinations made by
these methods require virtually 100% killing of the final
inoculum, which is strict requirement for any antimicrobial
agent [9]. In this study, the MBC of antibiotics for leptospires
and borreliae was defined as the lowest concentration of the
antibiotics at which no spirochetes were subcultured. The
macrolide antibiotic tilmicosin produced excellent in vitro
activity against all 6 strains of spirochetes tested. The MIC
and MBC of amoxicillin against Leptospira spp. were
higher than those of tilmicosin and enrofloxacin, and the
MBC of amoxicillin against Leptospira spp. was higher than
noted MICs. However, enrofloxacin was not effective
against B. burgdorferi tested, as shown by its high MIC and
MBC.
Tilmicosin is a novel long-acting macrolide antibiotic
developed exclusively for veterinary use [28]. As Mycotil, it
is used to treat bovine respiratory disease associated with
pasteurellae [16,23]. Tilmicosin (10 mg/kg, once) and
amoxicillin (15 mg/ml, once or twice) were effective in
cattle for resolving experimental leptospirosis caused by L.
borgpetersenii serovar Hardjo [3,32]. Enrofloxacin was
used concurrently with ampicillin in canine leptospirosis
and 83% of infected dogs survived [1]. Amoxicillin is
effective in treatment of canine Lyme disease [15]. However,
there are no data on the clinical use of enrofloxacin or
tilmicosin in borreliosis of animals.
Based upon our findings, tilmicosin was superior in vitro
on a microgram-per-milliliter basis when tested alongside
amoxicillin and enrofloxacin under identical test conditions
in EMJH or BSK-II media. Moreover, maximum
concentrations of tilmicosin in plasma after a subcutaneous
dose of 10 mg/kg to cattle are over 100 times higher than the
MIC against borreliae and tilmicosin has high volume of
distribution that selectively accumulates in solid tissues
[22,38]. The accumulation and concentration of tilmicosin
in tissues could be due to its lipophilic properties, which
favor passage through the lipid membrane of the cells. One
mechanism by which the diffusion of tilmicosin may have
led to enhance intracellular accumulation is the tendency of
basic compounds to be lysosomotropic and become trapped
in lysosomes as a result of the acidic pH [30]. The Lyme
borrelia reside in the acidic endosome and the use of a
lysosomotropic agent augments the clinical activity of
macrolide antibiotics in treatment of human patients with
chronic borreliosis [11]. Therefore, the potential role of
tilmicosin in the treatment of leptospirosis and Lyme disease
in some animal species merits further evaluation. Although
no significant adverse effects have been reported in cattle,
injections of Mycotil to horses, goats, swine, or nonhuman
primates can be fatal. Extensive studies on its safety in dogs
have not been performed. The heart is the target of toxicity
in animals, perhaps mediated via depletion of cardiac
intracellular calcium, resulting in a negative inotropic effect
[20]. Other formulations of the tilmicosin would be
necessary before it could be used in these species.
Table 2. In vitro susceptibility of 2 strains of Borrelia burgdorferi to 3 antimicrobial agents (µg/ml)
Amoxicillin Tilmicosin Enrofloxacin
MIC MBC MIC MBC MIC MBC
B. burgdorferi #15770 0.10 0.39 ≤0.01 0.05 50 ≥100
B. burgdorferi #2769 0.20 0.78 ≤0.01 0.02 12.5 ≥100
Range 0.05-0.39 0.20-0.78 ≤0.01 0.02-0.1 12.5-50.0 ≥100358 Doo Kim et al.
Classical macrolides and azalides frequently fail in the
therapy of early Lyme disease in human and clinical relapse
has been observed following conclusion of treatment [14,19,
27,37]. Moreover, it has been speculated that resistance may
develop in borreliae preexposed to erythromycin owing to
resistant subpopulations. We have evaluated antibiotic
treatment using tetracycline, doxycline, and ceftiofur in
experimental borreliosis of dogs and horses, however, most
of them can not completely eliminate the persistent infection
[6,33]. The lack of effective agents in the treatment of
animal borreliosis made it urgent to identify other potential
antibiotics. Therefore, further evaluation of the potential use
of a non-toxic formulation of tilmicosin in the treatment of
equine or canine leptopsirosis and/or borreliosis should be
confirmed.
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